Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

MRI scans aim to predict tysabri success in MS patients

NCT ID NCT02904876

First seen Mar 31, 2026 · Last updated Jun 22, 2026 · Updated 15 times

Summary

This study looked at whether special MRI scans can detect early brain changes in people with multiple sclerosis who are starting treatment with Tysabri. Researchers planned to follow 70 patients for two years, comparing MRI images before and after treatment. The goal was to find imaging markers that could predict how well someone responds to the drug. However, the study was terminated early, so the full results are not available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Service de Neurologie Hôpital de Hautepierre

    Strasbourg, Alsace, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tysabri (natalizumab)

What this could lead to

If successful, this could help doctors predict which MS patients will respond well to Tysabri using MRI scans.

What could go wrong

The study was terminated early, so results are limited. It was also small and exploratory, meaning findings may not be conclusive or widely applicable.

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.